New asthma shot could help kids breathe easier
NCT ID NCT07671001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The goal is to find better ways to control asthma in young children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
depemokimab (a biologic drug given as an injection)
What this could lead to
If successful, depemokimab could become a new add-on treatment option to help control asthma in young children with a specific type of inflammation.
What could go wrong
This is a small, early-phase study with only 30 children, so results may not apply broadly. The drug is still experimental, and side effects or lack of effectiveness are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••